2-(2-氧代哌啶-1-基)乙酸乙酯 | 22875-63-4

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 中文名称: 2-(2-氧代哌啶-1-基)乙酸乙酯
• 英文名称: ethyl (2-oxopiperidin-1-yl)acetate
• 英文别名: ethyl 2-(2-oxo-1-piperidinyl)acetate；1-(Carbethoxymethyl)-2-oxopiperidine；ethyl 2-(2-oxopiperidin-1-yl)acetate；2-Piperidon-N-essigsaeure-diethylester；(2-oxo-piperidin-1-yl)-acetic acid ethyl ester；Piperidon-(2)-N-essigsaeure-ethylester；1-(ethoxycarbonylmethyl)-2-piperidone；1-(ethoxycarbonylmethyl)-2-piperdone；ethyl 2-oxo-1-piperidineacetate；ethyl (2-piperidon-1-yl)acetate
• CAS: 22875-63-4
• 化学式: C₉H₁₅NO₃
• mdl: MFCD11189512
• 分子量: 185.223
• InChiKey: OWAWENPCRRJBOB-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.4
• 重原子数：
  13
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.78
• 拓扑面积：
  46.6
• 氢给体数：
  0
• 氢受体数：
  3

安全信息

• 海关编码：
  2933790090

反应信息

• 作为反应物：
  描述：

  2-(2-氧代哌啶-1-基)乙酸乙酯 在 sodium hydroxide 、 三乙基氯硅烷 、 三乙胺 、 sodium iodide 作用下， 反应 4.0h， 生成 <(+/-)-3-<2-(pyridin-4-yl)ethyl>-2-oxopiperidin-1-yl>acetic acid
  参考文献：
  名称：

  A Highly Efficient Synthesis of Fibrinogen Receptor Antagonist L-734,217 via a Novel Chemoselective Silyl-Mediated Conjugate Addition of δ-Lactams to 4-Vinylpyridine

  摘要：

  A highly practical chromatography-free six-step synthesis of L-734,217 suitable for large scale preparation is described. The key chiral pyridine acid intermediate (R)-1 was prepared in four steps based on a novel chemoselective silyl-mediated conjugate addition of ethyl (2-oxopiperidin-1-yl)acetate to 4-vinylpyridine and a highly productive, recyclable, kinetic resolution with quinine. Subsequent salt breaking/peptide coupling with benzyl 3-(R)-aminobutyrate (2) in a biphasic system, followed by concomitant hydrogenation of the pyridine ring and debenzylation afforded L-734,217 in 20% overall yield (30% with one recyle) from 2-piperidone. The mechanism of this key conjugate addition to 4-vinylpyridine was studied by C-13 NMR.

  DOI：

  10.1021/jo951214f
• 作为产物：
  描述：

  5-溴戊腈 在 三氟化硼乙醚 、 三乙胺 、 sodium iodide 作用下， 以 乙醇 为溶剂， 反应 58.0h， 生成 2-(2-氧代哌啶-1-基)乙酸乙酯
  参考文献：
  名称：

  Cycloadditions. 50. Multipath reactions between intramolecularly formed oxazolium salts and nucleophiles

  摘要：

  Reaction of 2-(4'-bromobutyl)-5-ethoxyoxazole (1) with nucleophiles led either to S(N)2 substitution products or to products with a piperidine skeleton. The latter were shown to arise from an intramolecular ring closure to an oxazolium salt 7, which was faster in the presence of a catalytic amount of NaI and in a polar solvent and for which NMR evidence is presented. The further transformation of 7 to 3-6 apparently involves addition of nucleophiles to 7 to produce 4-oxazoline 8 which opens to azomethine ylide 9. Neutralization of the latter occurred either via a proton shift, an alkyl shift, or via trapping by a dipolarophile (electron poor or electron rich). FMO calculations explain the preferred regiochemistry observed during trapping of ylide 9b.

  DOI：

  10.1021/jo00037a023

文献信息

• Regioselective synthesis of piperidinones by metal-catalyzed ring expansion-carbonylation reactions. Remarkable cobalt and/or ruthenium carbonyl catalyzed rearrangement and cyclization reactions
  作者：Ming De Wang、Howard Alper

  DOI：10.1021/ja00044a010

  日期：1992.8

  Carbonylation of pyrrolidines, catalyzed by cobalt carbonyl, results in the formation of piperidinones. The reaction is regiospecific in most cases, and the yield of product is increased when ruthenium carbonyl is present as a second catalyst. The dual catalytic system [Co 2 (CO) 8 /Ru 3 (CO) 12 ] is useful for the novel rearrangement of heterocyclic nitrogen ketones ((CH 2 ) n NCH 2 COR, n=4-7] to

  由羰基钴催化的吡咯烷的羰基化导致哌啶酮的形成。在大多数情况下，该反应是区域特异性的，当羰基钌作为第二催化剂存在时，产物的产率会增加。双催化体系 [Co 2 (CO) 8 /Ru 3 (CO) 12 ] 可用于杂环氮酮 ((CH 2 ) n NCH 2 COR, n=4-7] 在 72- 93% 的产率。2,6-二甲基哌啶基酮的一种不寻常的金属催化环化反应以 86-94% 的产率提供了 5,6,7,8-四氢茚茚
• Silica gel and microwave-promoted synthesis of dihydropyrrolizines and tetrahydroindolizines from enaminones
  作者：Robin Klintworth、Garreth L Morgans、Stefania M Scalzullo、Charles B de Koning、Willem A L van Otterlo、Joseph P Michael

  DOI：10.3762/bjoc.17.170

  日期：——

  various bromomethyl aryl and heteroaryl ketones, underwent cyclization in the presence of silica gel to give ethyl 6-(hetero)aryl-2,3-dihydro-1H-pyrrolizine-5-carboxylates within minutes upon microwave heating in xylene at 150 °C. Instead of functioning as a nucleophile, the enaminone acted as an electrophile at its carbonyl group during the cyclization. Yields of the bicyclic products were generally above

  通过N- (乙氧基羰基甲基)吡咯烷-2-硫酮与各种溴甲基芳基和杂芳基酮之间的 Eschenmoser 硫化物收缩制备多种N- (乙氧基羰基甲基)烯胺酮，在硅胶存在下进行环化，得到乙基 6-(杂）芳基-2,3-二氢-1H-吡咯嗪-5-甲酸酯在二甲苯中于 150 °C 下微波加热几分钟内即可生成。在环化过程中，烯胺酮在其羰基处充当亲电子试剂，而不是充当亲核试剂。双环产品的收率一般在75%以上。由 ( E )-2-[2-(2-氧代-2-芳基亚乙基)哌啶-1-乙酯生产 2-芳基-5,6,7,8-四氢中氮茚-3-甲酸乙酯的类似微波辅助反应[酰基]乙酸酯在非极性溶剂中失败，但在较低温度和微波功率下在乙醇中发生，尽管需要更长的时间。提出了一种可能的环化机制，并描述了二氢吡咯嗪核心中新产生的吡咯环的进一步官能化。
• Amnesia-reversal activity of a series of N-[(disubstituted-amino)alkyl]-2-oxo-1-pyrrolidineacetamides, including pramiracetam
  作者：Donald E. Butler、Ivan C. Nordin、Yvon J. L'Italien、Lynette Zweisler、Paul H. Poschel、John G. Marriott

  DOI：10.1021/jm00371a023

  日期：1984.5

  A series of N-[(dialkylamino)alkyl]-2-oxo-1- pyrrolidineacetamides was synthesized. The title compounds reversed electroconvulsive shock (ECS) induced amnesia in mice when administered subsequent to the ECS treatment and were inactive in a general observational test for central nervous system (CNS) activity. Active compounds exhibited an inverted U-shaped dose-response curve. Among the compounds with

  合成了一系列的N-[（（二烷基氨基）烷基] -2-氧-1-吡咯烷乙酰胺。在ECS治疗后给药时，标题化合物可逆转小鼠电惊厥（ECS）引起的健忘症，并且在中枢神经系统（CNS）活性的一般观察性测试中无效。活性化合物表现出倒U形剂量反应曲线。在具有最宽剂量反应曲线和最有效化合物的化合物中，有以N- [2- [双（1-（甲基乙基）氨基]乙基]乙基或2,6-二甲基哌啶基乙基为酰胺取代基的化合物。N-（二烷基氨基）取代基可显着增强健忘症的逆转活性，乙烯可提供最佳链长。选择N- [2- [双（1-甲基乙基）氨基]乙基] -2-氧-1-吡啶基乙酰胺N-（二烷基氨基）取代基进行临床前毒理学评估，指定研究编号CI-879和美国采用的名称（ USAN）pramiracetam。普拉西坦在动物中显示出广泛的安全性，并且在正常人类志愿者中耐受性良好。在一项开放性试验中，它对患有原发性变性痴呆（PDD或老年痴呆型老年痴呆）的患者显示出令人鼓舞的活性。
• Heterocycles useful in the treatment of benign prostatic hyperplasia
  申请人：Ortho-McNeil Pharmaceutical, Inc.

  公开号：US06384035B1

  公开（公告）日：2002-05-07

  This invention relates a to a series of heterocyclic substituted piperazines of Formula I pharmaceutical compositions containing them and intermediates used in their manufacture. The compounds of the invention selectively inhibit binding to the &agr;-1a adrenergic receptor, a receptor which has been implicated in benign prostatic hyperplasia. As such the compounds are potentially useful in the treatment of this disease.

  这项发明涉及一系列异环取代哌嗪的化合物I的制药组合物，以及用于其制备的中间体。该发明的化合物选择性地抑制与α-1a肾上腺能受体的结合，该受体已被认为与良性前列腺增生有关。因此，这些化合物在治疗这种疾病方面具有潜在的用途。
• Novel solid salt forms of N-[2-[4-[2-(1- methylethoxy)phenyl]-1-piperazinyl]-2-oxo-1piperidineacetamide
  申请人：——

  公开号：US20020082421A1

  公开（公告）日：2002-06-27

  The present invention relates to novel solid salt forms of N-[2-[4-[2-(1-methylethoxy)phenyl]-1-piperazinyl]ethyl]-2-oxo-1-piperidineacetamide and processes for their preparation.

  本发明涉及N-[2-[4-[2-(1-甲基乙氧基)苯基]-1-哌嗪基]乙基]-2-氧代-1-哌啶乙酰胺的新型固体盐形式及其制备方法。